RESEARCH PAPER |
|
Year : 2016 | Volume
: 7
| Issue : 4 | Page : 171-176 |
|
Comparison of efficacy, safety, and cost-effectiveness of rupatadine and olopatadine in patients of allergic rhinitis: A prospective, randomized, double-blind, parallel group study
Ganesh Dakhale1, Yogesh Tathod1, Seema Patel2, Sonali Pimpalkhute1, Latesh Raghute1, Ajita Khamkar1
1 Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India 2 Department of ENT, Government Medical College, Nagpur, Maharashtra, India
Correspondence Address:
Ganesh Dakhale Department of Pharmacology, Government Medical College, Nagpur - 440 003, Maharashtra India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0976-500X.195901
Clinical trial registration REF/2014/12/008163
|
|
Objective: To compare the efficacy, safety, and cost-effectiveness of rupatadine and olopatadine in patients of allergic rhinitis (AR). Materials and Methods: A 2-week, single-centered, randomized, double-blind, parallel group comparative clinical study was conducted on patients with AR. Following inclusion and exclusion criteria, 67 patients were recruited and randomized to two treatment groups and received the respective drugs for 2 weeks. At follow-up, parameters assessed were total nasal symptom score (TNSS), change in total and differential count of eosinophil. Results: In olopatadine group, there was a significantly higher reduction in TNSS (P < 0.05) than that of rupatadine. Both the drugs significantly reduced the absolute eosinophil count, but olopatadine (P < 0.001) was found to be superior. The incidence of adverse effects was found to be less in olopatadine group when compared with rupatadine group. Conclusion: Olopatadine is a better choice in AR in comparison to rupatadine due to its better efficacy and safety profile.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|